
There is no comprehensive study that compares the different usage strategies of zzso human zzso zzso in zzso zzso In order to clarify this issue, we conducted a prospective clinical zzso 

zzso patients were studied in three main zzso Group 1 zzso zzso 17) consisted of cancer patients without zzso These patients received zzso starting from the first chemotherapy zzso Group 2 zzso zzso 26) consisted of patients whose zzso zzso values decreased by at least 1 zzso after the first cycle of zzso Group 3 zzso zzso 34) consisted of patients whose zzso values dropped below zzso zzso after the second chemotherapy zzso Groups 2 and 3 were each divided into two zzso In groups 1, 2A and 3A zzso zzso zzso zzso three times a week) treatment was continued until three weeks after the completion of zzso In groups zzso and 3B, zzso was given for 12 weeks zzso 

There were no prominent differences between the zzso values of these groups throughout the chemotherapy zzso zzso rates and the number of patients who became anemic were also not different between zzso 

No zzso usage strategies are superior to others in terms of zzso levels and zzso zzso The decision as to when zzso is to be added to zzso therapy should be tailored to the health conditions of individual zzso 

